

Last five years research work of Amit Awasthi:

1. Roy S, **Awasthi A**. Metabolic checkpoints in differentiation of helper T cells in tissue inflammation. **Front Immunol.** 2019 Jan 14;9:3036. doi: 10.3389/fimmu.2018.03036
2. Roy S, **Awasthi A**. ATP Triggers Human Th9 Cell Differentiation via Nitric Oxide-Mediated mTOR-HIF1 α Pathway. **Front Immunol.** 2019 May 20;10:1120. doi: 10.3389/fimmu.2019.01120
3. Roy S and **Awasthi A**. Emerging roles of non-coding RNAs in T cell differentiation and functions in autoimmune diseases. **Int Rev Immunol.** 2019;38(5):232-245. doi: 10.1080/08830185.2019.1648454
4. Chandwaskar R, **Awasthi A**, Emerging roles of Th9 cells as an anti-tumor helper T cells. **Int Rev Immunol.** 2019;38(5):204-211. doi: 10.1080/08830185.2019.1648453
5. Sohail A, Abbas ZA, Ahuja V, **Awasthi A***, Srikanth CV. DeSUMOylase SENP7 mediated epithelial signalling triggers intestinal inflammation via expansion of Gamma-delta T cell. **Cell Rep.** 2019 Dec 10;29(11):3522-3538.e7. doi: 10.1016/j.celrep.2019.11.028 (*Co-corres. author).
6. Pal S, Medatwal N, Kumar S, Kar A, Komalla V, Yavvari PS, Mishra D, Rizvi ZA, Nandan S, Malakar D, Pillai M, **Awasthi A**, Das P, Sharma RD, Srivastava A, Sengupta S, Dasgupta U, Bajaj A. A localized chimeric hydrogel therapy combats tumor progression through alteration of sphingolipid metabolism. **ACS Cent Sci.** 2019 Oct 23;5(10):1648-1662. doi: 10.1021/acscentsci.9b00551
7. **Awasthi A**, Kumar H. T cell subtypes and its therapeutic potential in autoimmune diseases and cancer. **Int Rev Immunol.** 2019;38(5):181-182. doi: 10.1080/08830185.2019.1673472
8. Goswami R, **Awasthi A**. T Cell Differentiation and Function in Tissue Inflammation. **Front Immunol.** 2020 Feb 21;11:289. doi: 10.3389/fimmu.2020.00289.
9. Roy S, Asthana A, Goyal R, Yadav AK, **Awasthi A**. Proteome analysis revealed the essential functions of PP2A in the induction of Th9 cells. **Scientific Reports** 2020, 10:10992. doi: 10.1038/s41598-020-67845-2.
10. Samal S, Shrivastava T, Sonkusre P, Rizvi ZA, Kumar R, Ahmed S, Bansal M, Chauhan K, Pokhrel S, Tambare P, **Awasthi A**. Influenza A H1N1 M2e soluble immunogen derived from mammalian expression system form higher order oligomers and show enhanced immunogenicity in vivo. **J Biol Chem** 2020, jbc.RA120.013233. doi: 10.1074/jbc.RA120.013233.
11. Zhang H, Madi A, Yosef N, Chihara N, **Awasthi A**, Pot C, Lambden C, Srivastava A, Burkett PR, Nyman J, Christian E, Etmann Y, Lee A, Stroh H, Xia J, Karwacz K, Thakore PI, Acharya N, Schnell A, Wang W, Apetoh L, Rozenblatt-Rosen O, Anderson AC, Regev A, Kuchroo VK. IL-27 driven transcriptional network identifies regulators of IL-10 expression across T helper cell subset. **Cell Rep** 2020, 33:108433. doi: 10.1016/j.celrep.2020.108433.
12. Rampal R, Saurabh Kedia, **Awasthi A**, Ahuja A. Retinoic acid is elevated in the mucosa of patients with active ulcerative colitis and displays a pro-inflammatory role by augmenting IL-17 and IFN γ production. **Inflammatory Bowel Diseases** 2021, 27:74-83. doi: 10.1093/ibd/izaa121.
13. Mittal L, Srivastava M, Kumari A, Tonk RK, **Awasthi A***, Asthana S. The interplay among structural stability, plasticity and energetics is determined by conformational attuning of flexible loops of PD-1. **Journal of Chemical Information and Modelling** 2021, 61:358-384. doi: 10.1021/acs.jcim.0c01080. *Co-corresponding author.
14. Roy S, Rizvi ZA, Clarke A, Macdonald F, Pandey A, Zaiss D, Dr. Simon KA, **Awasthi A**. EGFR-HIF1 α signaling positively regulates the differentiation of IL-9 producing T helper cells. **Nat Commun.** 2021 Jun 1;12(1):3182. doi: 10.1038/s41467-021-23042-x
15. Sadhu S, Rizvi ZA, Pandey RP, Dalal R, Rathore DK, Kumar B, Pandey M, Kumar Y, Goel R, Maiti TK, Tiwari A, Pandey AK, **Awasthi A**. Gefitinib Results in Robust Host-Directed Immunity Against *Salmonella* Infection Through Proteo-Metabolomic Reprogramming. **Front Immunol.** 2021 Mar 31;12:648710. doi: 10.3389/fimmu.2021.648710

16. Vishwakarma P, Yadav N, Rizvi ZA, Khan NA, Chiranjivi A, Shrivastava T, Bansal M, Dwivedi P, Kumar R, **Awasthi A**, Ahmed S, Samal S. Characterization of SARS-CoV2 Spike Protein Synthetic Peptides as potential targets for vaccine and therapeutics. *Front Immunol.* **2021**, 12:613045. doi: 10.3389/fimmu.2021.613045.
17. Chauhan S, Rathore DK, Lacroix-Desmazes S, Gupta N, **Awasthi A**, Vrati S, Kalia M. Japanese encephalitis virus infected human monocyte-derived dendritic cells activate a transcriptional network leading to an antiviral inflammatory response. *Front Immunol.* **2021 Jun 17**;12:638694. doi: **10.3389/fimmu.2021.638694**
18. Ganneru B, Jogdand H, Dharam VK, Mulugu N, Prasad B S, Srinivas VK, Ella K, Ravikrishnan R, **Awasthi A**, Jose J, Rao P, Kumar D, Abraham P, Yadav P, Sapkal G, Shete A, Deshpande GR, Mohandas S, Basu A, Gupta N, Bhargava B, Mohan K, Ella R. Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152. *iScience* **2021**, 24 (4):102298. doi: 10.1016/j.isci.2021.102298.
19. Lin X, Gaudino S, Roy S, Castillo P, Elsegeiny W, Wakabayashi N, Oury TD, Pociask D, Chen K, **Awasthi A**, Kolls JK and Kumar P. Nrf2 differentially regulates IL-22 and IL-17A response in CD4+ T cells through Ahr and SOD3 axis. *Journal of Immunology* **2021**, 206 (7); 1540-1548; doi: 10.4049/jimmunol.1900656.
20. Yadav N, Vishwakarma P, Khatri R, Siddiqui G, **Awasthi A**, Ahmed S, Samal S. Comparative Immunogenicity analysis of Intra dermal and Intra muscular administration of SARS-CoV2 RBD epitope peptide-based Immunogen. *Microbes and Infection* **2021**, 23(4-5):104843. doi: 10.1016/j.micinf.2021.104843.
21. Shrivastava T, Singh B, Rizvi ZA, Verma R, Goswami S, Vishwakarma P, Jakhar K, Sonar S, Mani S, Bhattacharyya S, **Awasthi A**, Surjit M. Comparative immunomodulatory evaluation of the receptor binding domain of SARS CoV-2 spike protein; a potential vaccine candidate, imparts potent humoral and Th1 type of immune response in a mouse model. *Microbes Infect.* **2021 May-Jun**;23(4-5):104843. doi: **10.1016/j.micinf.2021.104843**
22. Rizvi ZA, Dalal R, Sadhu S, Kumar Y, Kumar S, Gupta SK, Tripathy MR, Rathore DK, **Awasthi A**. High salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity. *Sci Adv.* **2021 Sep 10**;7(37):eabg5016. doi: **10.1126/sciadv.abg5016**
23. Mittal L, Tonk RK, **Awasthi A**, Asthana S. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach. *Arch Biochem Biophys.* **2021 Nov 30**;713:109059. doi: **10.1016/j.abb.2021.109059**
24. Rizvi ZA, Tripathy MR, Sharma N, Goswami S, Srikanth N, Sastry JLN, Mani S, Surjit M, **Awasthi A***, Dikshit M. Effect of prophylactic use of intra-nasal oil formulation in the hamster model of Covid19. *Front Pharmacol.* **2021 Oct 14**;12:746729. doi: **10.3389/fphar.2021.746729**. eCollection **2021** *Co-corresponding author.
25. Thiruvengadam R, **Awasthi A**, Medigeshi GR, Bhattacharya S, Mani S, Sivasubbu S, Shrivastava S, Samal S, Murugesan DR, Desiraju BK, Kshetrapal P, Pandey R, Scaria V, Malik PK, Taneja J, Binayke A, Vohra T, Zaheer A, Rathore D, Khan NA, Shaman H, Ahmed S, Kumar R, Deshpande S, Subramani C, Wadhwa N, Gupta N, Pandey AK, Bhattacharya J, Agrawal A, Vrati S, Bhatnagar S, Garg PK. Cellular Immune Responses are Preserved and may Contribute to Vaccine Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. *Lancet Infect Dis.* **2022 Apr**;22(4):473-482. doi: **10.1016/S1473-3099(21)00680-0**
26. Thiruvengadam R, Binayke A, **Awasthi A**. SARS-CoV-2 delta variant – a persistent threat to the effectiveness of vaccines. *Lancet Infectious Disease* **2022**, 22(3):301-302. doi: 10.1016/S1473-3099(21)00697-6.
27. Suri C, **Awasthi A***, Asthana S. RoR γ t agonist, inverse agonists and allosteric inhibitors- a crystallographic landscape. *Drug Discov Today.* **2022 Feb**;27(2):652-663. doi: **10.1016/j.drudis.2021.11.022** *Co-corresponding author.
28. Rizvi ZA, Dalal R, Sadhu S, Binayke A, Dandotiya J, Kumar Y, Shrivastava T, Gupta SK, Aggarwal S, Tripathy M, Rathore DK, Yadav AK, Medigeshi GR, Pandey A, Samal S, Asthana A, **Awasthi A**. Golden

29. Thiruvengadam R, **Awasthi A**, Bhatnagar S, Garg PK. Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply. **Lancet Infectious Disease** **2022**, 22(4):447. doi: 10.1016/S1473-3099(22)00120-7.
30. Hingankar N, Deshpande S, Das P, Rizvi ZA, Burns A, Barman S, Zhao F, Ansari MY, Mukherjee S, Torres JL, Chattopadhyay S, Mehdi F, Sutar J, Rathore DK, Pargai K, Singh J, Sonar S, Jakhar K, Bhattacharyya S, Mani S, Singh S, Dandotiya J, Kshetrapal P, Thiruvengadam R, Batra G, Medigeshe G, Ward AB, Bhatnagar S, **Awasthi A**, Sok D, Bhattacharya J. A combination of potentially neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant, **PLoS Pathog.** **2022 Apr 28;18(4):e1010465. doi: 10.1371/journal.ppat.1010465**
31. Mittal L, Tonk R, **Awasthi A**, Asthana S. Traversing through the dynamic protein-protein interaction landscape and conformational plasticity of PD-1 for small molecule discovery. **J Med Chem.** **2022 Apr 28;65(8):5941-5953. doi: 10.1021/acs.jmedchem.2c00176**
32. Khatri R, Parray HA, Agrahari AK, Rizvi ZA, Kaul R, Raj S, Asthana S, Mani S, Sweetey Samal, **Awasthi A**, Ahmed S. Designing and characterization of a SARS-CoV-2 immunogen with receptor binding motif grafted on a protein scaffold: An epitope-focused vaccine approach. **Int J Biol Macromol.** **2022 Jun 1;209(Pt A):1359-1367. doi: 10.1016/j.ijbiomac.2022.04.148**
33. Kumar CS, Singh B, Rizvi ZA, Parray HA, Verma JK, Ghosh S, Mukhopadhyay A, **Awasthi A**, Shrivastava T, Banerjee M. Virus-like particles of SARS-CoV-2 as virus surrogates: morphology, immunogenicity, and internalization in neuronal cells. **ACS Infect Dis.** **2022 Oct 14;8(10):2119-2132. doi: 10.1021/acscinfecdis.2c00217**
34. Rizvi ZA, Babele P, Sadhu S, Madan U, Tripathy MR, Goswami S, Shailendra Mani, Kumar S, Awasthi A, Dikshit M. Prophylactic treatment of *Glycyrrhiza glabra* mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis. **Front Immunol.** **2022 Sep 27;13:945583. doi: 10.3389/fimmu.2022.945583**
35. Binayke A, Zaheer A, Dandotiya Y, Kumar Y, Mani S, Madan U, Tripathy MR, Gupta SK, Shrivastava T, Rathore DK, Pandey AK, Awasthi A. Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19. **Vaccines (Basel).** **2022 Oct 20;10(10):1762. doi: 10.3390/vaccines10101762**
36. Thuluva S, Paradkar V, Turaga K, Gunneri SR, Yerroju V, Mogulla R, Suneetha PV, Kyasani M, Manoharan SK, Adabala S, Javvadi AS, Medigeshe G, Singh J, Shaman H, Binayke A, Zaheer A, **Awasthi A**, Singh C, Rao AV, Basu I, Khobragade AK, Pandey AK. Immunogenic superiority and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter, randomized clinical trial. **Hum Vaccin Immunother.** **2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632.**
37. Roy SS, Sharma S, Rizvi ZA, Sinha D, Gupta D, Rophina M, Sehgal P, Sadhu S, Tripathy MR, Samal S, Maiti S, Scaria V, Sivasubbu S, **Awasthi A**, Harshan KH, Jain S, Chowdhury S. G4-binding drugs, chlorpromazine and prochlorperazine, repurposed against COVID-19 infection in hamsters. **Front Mol Biosci.** **2023 Mar 16;10:1133123. doi: 10.3389/fmolb.2023.1133123.**
38. Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Pothakamuri SV, Turaga K, Kyasani M, Manoharan S, Adabala S, Javvadi AS, Medigeshe GR, Singh J, Shaman H, Binayke A, Aymaan Z, **Awasthi A**, Narang M, Pradeep N, Mahantshetti N, Garg BS, Ravi M. Safety, tolerability and immunogenicity of Biological Es CORBEVAX vaccine in children and adolescents: A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study. **Vaccine.** **2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31**
39. Parray HA, Narayanan N, Garg S, Rizvi ZA, Shrivastava T, Kushwaha S, Singh J, Murugavelu P, Anbalagan A, Mehdi F, Raj N, Singh S, Dandotiya J, Lukose A, Jamwal D, Kumar S, Chiranjivi A, Dhyani S, Mishra N, Jakhar K, Sonar S, Panchal AK, Tripathy MR, Ahamed S, Samal S, Mani S, Bhattacharyya S, Das S, Sinha S, Luthra L, Batra G, Sehgal D, Medigeshe G, Sharma C, **Awasthi A***, Garg PK, Nair DT, Kumar R. A broadly neutralising monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV2 variant of concerns. (*Co-corresponding author). **PLoS Pathog.** **2022 Dec 12;18(12):e1010994. doi: 10.1371/journal.ppat.1010994.**

40. Rizvi, Z.A., Babel, P., Madan, U., Sadhu, S., Tripathy, M.R., Goswami, S., Mani, S., Dikshit, M. and **Awasthi, A.** 2023, Pharmacological potential of Withania somnifera (L.) Dunal and Tinospora cordifolia (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. **Frontiers in Immunology** 2023, Mar 7;14:1138215. doi: 10.3389/fimmu.2023.1138215.
41. Saxena R, Sharma P, Kumar S, Agrawal N, Sharma SK, **Awasthi A**, Modulation of Mitochondria by Viral Proteins. **Life Sci.** 2023 Jan 15;313:121271. doi: 10.1016/j.lfs.2022.121271
42. Khatri, Ritika, Gazala Siddiqui, Srikanth Sadhu, Vikas Maithil, Preeti Vishwakarma, Bharat Lohiya, Abhishek Goswami, Shubbir Ahmed, Amit Awasthi, and Sweetie Samal. "Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. **Med Microbiol Immunol.** 2023 Feb;212(1):103-122. doi: 10.1007/s00430-022-00760-7
43. Sadhu S, Dalal R, Dandotia J, Binayke A, Vinayak KV, Shakti K, Singh V, Goswami S, Tripathy MR, Rizvi ZA, Awasthi A. IL-9 exacerbates SARS-CoV2 infection and associated airway inflammation. **Nat Commun.** 2023 Jul 10;14(1):4060. doi: 10.1038/s41467-023-39815-5.
44. Ansari S, Gupta N , Verma R , Singh O , Gupta J , Kumar a ,Yadav M , Binayke A ,Tiwari M, Periwal N, Sood V , Mani S, **Awasthi A** , Shalimar ,Nayak B , Ranjith CT, Surjit M.K, Antiviral activity of the human endogenous retrovirus-R envelope protein against SARS-CoV-2. **EMBO reports** 2023, 24 (7), e55900
45. Rizvi ZA, Sharma K, Srikanth S, Dandotiya J, Khatri R, Singh V, Adhikari N, Das V, Mani S, Samal S, **Awasthi A***. Omicron sub-lineage BA.5 infection causes attenuated pathology and results in robust protection in Omicron-recovered hACE2 transgenic mice. **Commun Biol.** 2023 Sep 13;6(1):935. doi: 10.1038/s42003-023-05263-6
46. Rizvi, Z. A., Madan, U., Tripathy, M. R., Goswami, S., Mani, S., **Awasthi, A.**, & Dikshit, M. (2023). Evaluation of Ayush-64 (a Polyherbal Formulation) and Its Ingredients in the Syrian Hamster Model for SARS-CoV-2 Infection Reveals the Preventative Potential of Alstonia scholaris. **Pharmaceuticals (Basel).** 2023 Sep 21;16(9):1333. doi: 10.3390/ph16091333
47. Thiruvengadam R, Rizvi ZA, Raghavan S, Murugesan DR, Gosain M, Dandotiya J, Ayushi, Samal S, Pandey AK, Wadhwa N, Bhatnagar S, **Awasthi A**, Garg PK. Clinical and experimental evidence suggest omicron variant of SARS-CoV-2 is inherently less pathogenic than delta variant independent of previous immunity. **Eur J Med Res.** 2023 Oct 11;28(1):421. doi: 10.1186/s40001-023-01373-3
48. Mittal L, Rajiv K. Tonk, Awasthi A, Shailendra Asthana. Harnessing the druggability at orthosteric and allosteric sites of PD-1 for small molecule discovery by an integrated in silico pipeline, **Comput Biol Chem.** 2023 Dec;107:107965. doi: 10.1016/j.compbiolchem.2023.107965
49. Sadhu S, Dandotiya J, Dalal R, Khatri R, Anna Z. Mykytyn, Aashima Batra, Manpreet Kaur, Rucha Chandwaskar, Virendra Singh, Aarzoo Kamboj, Mitul Srivastava, Shailendra Mani, Shailendra Asthana, Sweetie Samal, Zaigham Abbas Rizvi, Deepak B. Salunke, Bart L. Haagmans, Awasthi A. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry. **Antiviral Res.** 2023 Dec;220:105743. doi: 10.1016/j.antiviral.2023.105743
50. Misra P, Garg P K, Awasthi A, Kant S, Rai SK, Mohammad Ahmad, Guleria R, Deori T.J, Mandal S, Jaiswal A, Gongal G, Vishwakarma S, Bairwa M, Kumar R, Haldar P, Binayke A: Cell-Mediated Immunity (CMI) for SARS-CoV-2 Infection Among the General Population of North India: A Cross-Sectional Analysis From a Sub-sample of a Large Sero-Epidemiological Study. **Cureus.** 2023 Nov 15;15(11):e48824. doi: 10.7759/cureus.48824
51. Binayke A, Zaheer A, Vishwakarma S, Singh S, Sharma P, Chandwaskar R, Gosain M, Raghavan S, Murugesan D.R, Kshetrapal P, Thiruvengadam R, Bhatnagar S, Pandey A.K, Garg P.K, Amit Awasthi A. A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation. **NPJ Vaccines.** 2024 Jan 2;9(1):3. doi: 10.1038/s41541-023-00794-9
52. Ahmed N, Athavale A, Tripathi A.H, Subramaniam A, Upadhyay S.K, Pandey A.K, Ramesh Chandra Rai R.C, **Awasthi A**. To be remembered: B cell memory response against SARS-CoV-2 and its variants in vaccinated and unvaccinated individuals. **Scand J Immunol.** 2024 Feb;99(2):e13345. doi: 10.1111/sji.13345
53. Tyagi, S., Sadhu, S., Sharma, T., Paul, A., Pandey, M., Nain, V. K., ... & Pandey, A. K. VapC12 ribonuclease toxin modulates host immune response during Mycobacterium tuberculosis infection. **Front Immunol.** 2024 Mar 7;15:1302163. doi: 10.3389/fimmu.2024.1302163

54. Sasi, A, Dandotiya, J, Kaushal, J, Ganguly, S, Binayke, A, Ambika, K.M, Shree, A., Jahan, F, Sharma, P, Sun, T.M, and **Awasthi A**, Bakhshi S. Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study. *Vaccine*. 2024 Apr 11;42(10):2722-2728. doi: 10.1016/j.vaccine.2024.03.042
55. Tyagi, S., Sadhu, S., Pandey, M., Nain, V.K., Rathore, D.K., Chatterjee, S., Awasthi, A. and Pandey, A.K., VapC12 ribonuclease toxin modulates host immune response during Mycobacterium tuberculosis infection. *Front Immunol*. 2024 Mar 7;15:1302163. doi: 10.3389/fimmu.2024.1302163
56. Kedla S, Virmani S, Bajaj A, Markandey M, Singh N, Madan D, Kaushal K, Sahu P, Vuyyuru SK, Kante B, Kumar P, Thomas DM, Mundhra SK, Singh MK, Verma M, Sharma R, Das P, Dash NR, Monga N, **Awasthi A**, Makharia G, Ahuja V. Coconut Water Induces Clinical Remission in Mild to Moderate Ulcerative Colitis: Double-blind Placebo-controlled Trial. *Clin Gastroenterol Hepatol*. 2024 Jun;22(6):1295-1306.e7. doi: 10.1016/j.cgh.2024.01.013
57. Rizvi ZA, Sadhu S, Dandotiya J, Sharma P, Binayke A, Singh V, Das V, Khatri R, Kumar R, Samal S, Kalia M, **Awasthi A**. SARS-CoV-2 infection induces thymic atrophy mediated by IFN γ in hACE2 transgenic mice. *Eur J Immunol*. 2024 Jul;54(7):e2350624. doi: 10.1002/eji.202350624
58. Madan U, Verma B, **Awasthi A**, Cenriciviroc, a CCR2/CCR5 antagonist, promotes the generation of Type 1 regulatory T cells. *Eur J Immunol*. 2024 Jul;54(7):e2350847. doi: 10.1002/eji.202350847
59. Gosain TP, Chugh S, Rizvi ZA, Chauhan NK, Kidwai S, Thakur KG, **Awasthi A**, Singh Ramandeep. Mycobacterium tuberculosis strain with deletions in menT3 and menT4 is attenuated and confers protection in mice and guinea pigs. *Nat Commun*. 2024 Jun 27;15(1):5467. doi: 10.1038/s41467-024-49246-5
60. Agrawal T, Siddiqui G, Dahiya R, Patidar A, Madan U, Das S., Asthana S, Samal S. and **Awasthi A**, Inhibition of early RNA replication in Chikungunya and Dengue virus by lycorine: In vitro and in silico studies. *Biochem Biophys Res Commun*. 2024 Jul 11;730:150393. doi: 10.1016/j.bbrc.2024.150393
61. Deka A, Kumar N, Basu S, Chawla M, Bhattacharya N, Ali SK, Bhawna, Madan U, Kumar S, Das B, Sengupta D, **Awasthi A**, Basak S. Non-canonical NF- κ B signalling limits the tolerogenic β -catenin-Raldh2 axis in gut dendritic cells to exacerbate intestinal pathologies. *EMBO J*. 2024 Jul 25. doi: 10.1038/s44318-024-00182-6
62. Narayan S, Dalal R, Rizvi ZA, **Awasthi A***. Zinc dampens anti-tumor immunity by promoting Foxp3+ regulatory T cells. *Frontiers in Immunology* 2024, 10.3389/fimmu.2024.1389387 (Accepted and ahead for publication)
63. Binayke A, Zaheer A, Vishwakarma S, Sharma P, Dandotiya J, Raghavan S, Gosain M, Singh S, Chattopadhyay S, Kaushal J, Madan U, Kshetrapal P, Batra G, Wadhwa N, Pandey A.K, Bhatnagar S, Garg P.K, **Awasthi A*** Understanding the landscape of the SARS-CoV-2-specific T cells post Omicron Surge. *Accepted in The Journal of Medical Virology*



प्रो. जी. नार्थिकयम / Prof. G. Narthikayam
 कार्यकारी निदेशक / Executive Director
 वैद्यकसम्वैसी-दवासेकनन स्वस्थ विज्ञान एवं प्रौद्योगिकी संस्थान
 प्रेर प्रौद्योगिकी अनुसंधान और नवाचार परिषद, सेक्टर 1, नोएडा, भारत सरकार
 इलीयार बायोटेक विज्ञान केंद्र, कलकत्ता-700011
 IIRC-Translational Health Science and Technology Institute
 Biotechnology Research and Innovation Council, DBT, Govt. of India
 NCR Biotech Science Cluster, Faridabad - 121 001 Haryana